| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Phillips), University of Virginia, Charlottesville, VA, and the Department of Preventive Medicine and Environmental Health (Dr. Torner), University of Iowa, Iowa City, IA.
Presented in part at the 45th annual meeting of the American Academy of Neurology, New York, NY, April 25-May 1, 1993.
Received December 28, 1994. Accepted in final form March 8, 1996.
Address correspondence and reprint requests to Dr Phillips, Box 394, Department of Neurology, University of Virginia, Charlottesville, VA 22908.
Objective: To survey the epidemiologic literature for evidence of an increasing prevalence of myasthenia gravis (MG) over time, and to explore the reasons for the increase. Data Sources: We found population-based reports of the epidemiology of MG by searching bibliographic databases. We used MG, epidemiology, prevalence, incidence, and mortality as search terms. Study Selection: We included population-based studies that reported the number of cases and the time period from which rates were calculated. Statistical Methods: We performed a regression analysis of rates versus date of study, comparing the slopes of regression lines for prevalence, incidence, and mortality. We performed a second analysis grouping rates by decade of study and calculating a mean rate weighted by the size of the population studied. We calculated 95% confidence intervals for each rate. Results: We included 33 studies from 1950 through 1995. Prevalence and incidence rates increased over time, but the regression line for prevalence significantly exceeded that for incidence. Mortality rates declined slightly. The weighted means for prevalence rose significantly, but there was no significant change in incidence or mortality. Conclusion: The prevalence of MG has increased over the past forty-five years, probably because patients with the disease have longer life spans owing to present-day treatment.
NEUROLOGY 1996;47: 1233-1238
This article has been cited by other articles:
|
|
 |
|
  A. T. Heldal, J. F. Owe, N. E. Gilhus, and F. Romi SEROPOSITIVE MYASTHENIA GRAVIS: A NATIONWIDE EPIDEMIOLOGIC STUDY Neurology, July 14, 2009; 73(2): 150 - 151. [Full Text] [PDF]
|
|
|
|
|
|
A. Alshekhlee, J. D. Miles, B. Katirji, D. C. Preston, and H. J. Kaminski Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals Neurology, May 5, 2009; 72(18): 1548 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Hill and Y Ben-Shlomo Neurological care and risk of hospital mortality for patients with myasthenia gravis in England J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 421 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H Niks, J. B M Kuks, and J. J G M Verschuuren Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 417 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J F Owe, A K Daltveit, and N E Gilhus Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001 J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 203 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Scherer, R. S. Bedlack, and D. L. Simel Does This Patient Have Myasthenia Gravis? JAMA, April 20, 2005; 293(15): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Oopik, A-E Kaasik, and J Jakobsen A population based epidemiological study on myasthenia gravis in Estonia J. Neurol. Neurosurg. Psychiatry, December 1, 2003; 74(12): 1638 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Poulas, E Tsibri, A Kokla, D Papanastasiou, T Tsouloufis, M Marinou, P Tsantili, T Papapetropoulos, and S J Tzartos Epidemiology of seropositive myasthenia gravis in Greece J. Neurol. Neurosurg. Psychiatry, September 1, 2001; 71(3): 352 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Romi, G. O. Skeie, J. A. Aarli, and N. E. Gilhus The Severity of Myasthenia Gravis Correlates With the Serum Concentration of Titin and Ryanodine Receptor Antibodies Arch Neurol, November 1, 2000; 57(11): 1596 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kissel and G. M. Franklin Treatment of myasthenia gravis: A call to arms Neurology, July 12, 2000; 55(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
K. Poulas, E. Tsibri, D. Papanastasiou, T. Tsouloufis, M. Marinou, P. Tsantili, T. Papapetropoulos, and S. J. Tzartos Equal male and female incidence of myasthenia gravis Neurology, March 14, 2000; 54(5): 1202 - 1203. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Aarli Late-Onset Myasthenia Gravis: A Changing Scene Arch Neurol, January 1, 1999; 56(1): 25 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N P Robertson, J Deans, and D A S Compston Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England J. Neurol. Neurosurg. Psychiatry, October 1, 1998; 65(4): 492 - 496. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
